Roivant Sciences Ltd. (ROIV)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Roivant Sciences Ltd. (ROIV)
Go deeper and ask any question about ROIV
Company Performance
Current Price
as of Sep 13, 2024$11.94
P/E Ratio
2.14
Market Cap
$8.83B
Description
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Metrics
Overview
- HQLondon, GL
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerROIV
- Price$11.94-1.49%
Trading Information
- Market Cap$8.83B
- Float59.96%
- Average Daily Volume (1m)5,098,333
- Average Daily Volume (3m)5,062,736
- EPS$5.91
Company
- Revenue$158.30M
- Rev Growth (1yr)154.96%
- Net Income$95.30M
- Gross Margin88.19%
- EBITDA Margin-409.36%
- EBITDA-$225.69M
- EV$3.42B
- EV/Revenue21.58
- P/E2.14
- P/S58.95
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia